USA flag logo/image

An Official Website of the United States Government

Electrochemical Quantification of HCV RNA

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75914
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
AI065178
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ALDERON BIOSCIENCES, INC.
120 Turner Street Beaufort, NC 28516-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Electrochemical Quantification of HCV RNA
Agency: HHS
Contract: 1R43AI065178-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): The National Institutes of Allergy and Infectious Disease have called for better tools for the detection and diagnosis of emerging and re-emerging infectious diseases. To meet this need, Alderon Biosciences Inc. (ABI) proposes to develop innovative, low-cost tests with sensitivity adequate for determining HCV viral load. Reliable and affordable HCV viral load tests would aid in detection and treatment of liver disease. HCV is one of the most important causes of chronic liver disease, affecting about 2% of the U.S. population and causing 10,000 to 12,000 deaths annually. Although quantitative molecular assays for HCV RNA are highly advised, the high cost (above $100), technical difficulty and variability of current tests constitute a major problem for HCV diagnosis and treatment. ABI proposes to develop rapid, facile, and lower cost (less than $25) tests to quantify levels of HCV RNA at clinically significant levels without use of PCR that do not require expensive equipment and can be done in physician's offices or regional public health laboratories. The technical approach involves a primer-extension signal amplification method (PESA) and capillary-flow sensor elements for sensitive and facile execution of low-cost tests. The instrument and sensor elements will be designed and developed so that HCV viral load measurements will use less assay time, fewer steps, and much lower set-up and per-result cost than the current state-of-the-art nucleic acid probe-based system. Preliminary investigation indicates a significant market for the proposed technology in research and public health applications over the next 3-to 5-year period as the demand increases for simpler, more accessible, and widely applicable tools for molecular assays to measure clinical samples for viral load in the diagnosis, treatment, and control of infections such as HCV.

Principal Investigator:

Robert W. Henkens
9195448220
HENKENS@EARTHLINK.NET

Business Contact:


9195448220
Small Business Information at Submission:

Alderon Biosciences, Inc.
Alderon Biosciences, Inc. 2810 Meridian Pky, Ste 152 Durham, NC 27713

EIN/Tax ID: 561458171
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No